Fairmount Funds Management LLC 4

What Happened
Fairmount Funds Management LLC, reported as a director, was granted a derivative award on 2026-06-09 representing the right to purchase 7,657 shares of Apogee Therapeutics (APGE). The Form 4 lists the acquisition amount as $0.00 (derivative instrument). Per the filing, the option will vest on the one-year anniversary of the grant date, subject to the reporting person’s continued service.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (filed within the standard 2-business-day window).
• Instrument: Option/derivative award for 7,657 shares; reported acquisition price $0.00.
• Vesting: Award vests one year after grant, subject to continued service.
• Beneficial ownership notes: Tomas Kiselak (a Managing Member of Fairmount who serves on Apogee’s board) holds the option for one or more investment vehicles managed by Fairmount; he must turn over net cash or stock received to the Fairmount Fund(s) and disclaims beneficial ownership. Fairmount also disclaims beneficial ownership except for any pecuniary interest.
• Shares owned after the transaction: not specified in the details provided.

Context
This filing reports a grant/award (derivative option), not an open-market purchase or sale. For retail investors, option grants indicate potential future ownership if vesting and any exercise conditions are met; they are not immediate purchases of common stock. The disclosable arrangement shows the option is held for investment vehicle(s) managed by Fairmount and that Mr. Kiselak and Fairmount disclaim direct beneficial ownership beyond any pecuniary interest.